By Fineline Cube Sino Biopharmaceutical Limited (HKG: 1177) announced the presentation of first-in-human Phase I clinical study results for its Category 1 drug candidate Kylo-0603 at the European Association for the Study of the Liver (EASL) Congress 2026. The small-molecule thyroid hormone receptor beta (THR-β) agonist demonstrated clinically meaningful lipid-lowering effects and a favorable safety profile in healthy subjects, positioning it as a potential novel therapy for dyslipidemia and metabolic liver diseases.
Clinical Study Overview
| Component | Detail |
|---|---|
| Company | Sino Biopharmaceutical Limited (HKG: 1177) |
| Product | Kylo-0603 – small-molecule THR-β agonist (Category 1 drug candidate) |
| Study Phase | First-in-human Phase I |
| Population | Healthy subjects |
| Study Design | Multiple ascending dose (MAD) study |
| Primary Objectives | Safety, tolerability, pharmacokinetics, and pharmacodynamics |
| Presentation Venue | European Association for the Study of the Liver (EASL) Congress 2026 |
Key Efficacy Results – Lipid-Lowering Effects
| Dose Group | Placebo-Adjusted LDL-C Reduction (Day 15) | Statistical Significance |
|---|---|---|
| 8 mg | Clinically meaningful reduction | p < 0.05 |
| 12 mg | 28.5% reduction (greatest effect) | p < 0.05 |
| 16 mg | Clinically meaningful reduction | p < 0.05 |
Additional Lipid Parameter Improvements
- Total cholesterol: Significant reductions observed across active dose groups
- Apolipoprotein B: Statistically significant decreases demonstrating impact on atherogenic particles
- Triglycerides: Meaningful reductions supporting comprehensive lipid-modifying activity
The 12 mg dose emerged as the optimal balance between efficacy and safety, achieving the maximum LDL-C reduction of 28.5%.
Safety & Tolerability Profile
- Adverse Events (AEs): No treatment-related or dose-related trends observed
- Serious Adverse Events: None reported across all dose groups
- Safety Profile: Favorable with no significant safety signals identified
- Tolerability: Well-tolerated across the 8-16 mg dose range
- Discontinuation Rate: No subjects discontinued due to adverse events
The absence of dose-related adverse events suggests a wide therapeutic window for Kylo-0603, a critical advantage for chronic metabolic disease treatment.
Therapeutic Rationale & Market Opportunity
| Clinical Need | Kylo-0603 Solution |
|---|---|
| Residual Cardiovascular Risk | Novel mechanism targeting THR-β pathway for comprehensive lipid management |
| Statins Intolerance | Alternative mechanism for patients unable to tolerate statin therapy |
| Combination Therapy Gap | Potential for use alongside existing lipid-lowering agents |
| Metabolic Liver Disease | THR-β activation may address both dyslipidemia and NAFLD/NASH |
| Treatment Adherence | Oral small-molecule formulation enables convenient daily dosing |
THR-β agonists represent an emerging class of lipid-modifying agents that work through a distinct mechanism from statins, PCSK9 inhibitors, and other established therapies.
Competitive Landscape Context
- THR-β Class Validation: Resmetirom’s recent approval for NASH provides clinical validation of the target
- Differentiation Strategy: Kylo-0603’s 28.5% LDL-C reduction compares favorably to other THR-β agonists in development
- Dual Indication Potential: Lipid-lowering efficacy supports development for both cardiovascular risk reduction and metabolic liver disease
- China Innovation Leadership: Category 1 designation reflects domestic innovation in novel metabolic therapeutics
- Global Development Pathway: Strong Phase I data supports potential international expansion
Next Development Steps
- Phase II Planning: Dose selection for proof-of-concept studies in dyslipidemia and/or NASH populations
- Indication Strategy: Evaluation of optimal initial indication (pure dyslipidemia vs. metabolic liver disease)
- Combination Studies: Potential exploration of Kylo-0603 with statins or other lipid-lowering agents
- Regulatory Pathway: Engagement with Chinese and international regulatory authorities on development plan
- Manufacturing Scale-up: Preparation for larger clinical trials and potential commercial production
Forward-Looking Statements
This brief contains forward-looking statements regarding Sino Biopharmaceutical’s Kylo-0603 development program, including clinical development plans, regulatory pathways, and market potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and evolving treatment paradigms in dyslipidemia and metabolic liver disease.-Fineline Info & Tech